NASDAQ:PSNLPersonalis Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Personalis Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $7.92 -0.34 (-4.12 %) (As of 04/7/2020 03:19 PM ET) Add Compare Share Today's Range$7.87Now: $7.92▼$8.2950-Day Range$4.75MA: $7.79▼$10.4852-Week Range$4.27Now: $7.92▼$31.88Volume4,323 shsAverage Volume527,745 shsMarket Capitalization$249.24 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsAdvanced ChartEarningsInsider TradesInstitutional OwnershipHeadlinesSocial Media Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies. It offers NeXT Platform, which provides data for cancer therapy development, personalized therapies, therapy selection, and diagnostics. The company also provides a complementary liquid biopsy assay that analyzes various human genes versus. It serves approximately 45 biopharmaceutical customers, including a range of pharmaceutical companies. The company was founded in 2011 and is headquartered in Menlo Park, California.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingPersonalis has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $22.50, Personalis has a potential upside of 184.1% from its current price of $7.92.Amount of Analyst CoveragePersonalis has only been the subject of 1 research reports in the past 90 days. Previous Next 2.5 Community Rank Outperform VotesPersonalis has received 53 “outperform” votes. (Add your “outperform” vote.)Underperform VotesPersonalis has received 52 “underperform” votes. (Add your “underperform” vote.)Community SentimentPersonalis has received 50.48% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Personalis and other stocks. Vote “Outperform” if you believe PSNL will outperform the S&P 500 over the long term. Vote “Underperform” if you believe PSNL will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldPersonalis does not currently pay a dividend.Dividend GrowthPersonalis does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Personalis insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $893,610.00 in company stock.Percentage Held by Institutions55.78% of the stock of Personalis is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Personalis are expected to decrease by -19.35% in the coming year, from ($0.93) to ($0.75) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Personalis is -5.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Personalis is -5.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPersonalis has a P/B Ratio of 2.32. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.40 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Medical laboratories Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:PSNL Previous Symbol CUSIPN/A CIKN/A Webhttp://www.personalis.com/ Phone650-752-1300Debt Debt-to-Equity RatioN/A Current Ratio2.79 Quick Ratio2.70Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$65.21 million Price / Sales3.82 Cash FlowN/A Price / Cash FlowN/A Book Value$3.42 per share Price / Book2.32Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees147 Outstanding Shares31,470,000Market Cap$249.24 million Next Earnings Date6/24/2020 (Estimated) OptionableNot Optionable Receive PSNL News and Ratings via Email Sign-up to receive the latest news and ratings for PSNL and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:PSNL Rates by TradingView Personalis (NASDAQ:PSNL) Frequently Asked Questions How has Personalis' stock been impacted by COVID-19 (Coronavirus)? Personalis' stock was trading at $6.02 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, PSNL shares have increased by 31.6% and is now trading at $7.92. View which stocks have been mosted impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Personalis? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Personalis in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Personalis. When is Personalis' next earnings date? Personalis is scheduled to release its next quarterly earnings announcement on Wednesday, June 24th 2020. View our earnings forecast for Personalis. How were Personalis' earnings last quarter? Personalis (NASDAQ:PSNL) announced its earnings results on Wednesday, March, 25th. The company reported ($0.21) earnings per share for the quarter, topping analysts' consensus estimates of ($0.25) by $0.04. The firm earned $18.15 million during the quarter, compared to analyst estimates of $17.75 million. View Personalis' earnings history. What price target have analysts set for PSNL? 5 brokerages have issued twelve-month target prices for Personalis' shares. Their forecasts range from $13.00 to $29.00. On average, they anticipate Personalis' stock price to reach $22.50 in the next twelve months. This suggests a possible upside of 184.1% from the stock's current price. View analysts' price targets for Personalis. Has Personalis been receiving favorable news coverage? News headlines about PSNL stock have trended very negative recently, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Personalis earned a news impact score of -3.3 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View the latest news aboutPersonalis. Who are some of Personalis' key competitors? Some companies that are related to Personalis include CareDx (CDNA), Castle Biosciences (CSTL), RadNet (RDNT), Centogene (CNTG), Fulgent Genetics (FLGT), DermTech (DMTK), Enzo Biochem (ENZ), Anpac Bio-Medical Science (ANPC), Celcuity (CELC), Biocept (BIOC), Psychemedics (PMD), OpGen (OPGN), Miragen Therapeutics (MGEN), Avant Diagnostics (AVDX) and CBA Florida (CBAI). What other stocks do shareholders of Personalis own? Based on aggregate information from My MarketBeat watchlists, some companies that other Personalis investors own include Editas Medicine (EDIT), NIO (NIO), Precision BioSciences (DTIL), Enphase Energy (ENPH), Flexion Therapeutics (FLXN), Heron Therapeutics (HRTX), Inovio Pharmaceuticals (INO), Intellia Therapeutics (NTLA), Proteostasis Therapeutics (PTI) and Zynerba Pharmaceuticals (ZYNE). Who are Personalis' key executives? Personalis' management team includes the following people: Mr. John West, Co-Founder, CEO, Pres & Director (Age 62)Prof. Russ B. Altman M.D., Ph.D., Co-Founder and Member of Clinical & Scientific Advisory BoardMr. Euan A. Ashley, Co-Founder and Member of Clinical & Scientific Advisory BoardDr. Atul Butte, Co-Founder and Member of Clinical & Scientific Advisory BoardDr. Michael Snyder Ph.D., Co-Founder and Member of Clinical & Scientific Advisory Board When did Personalis IPO? (PSNL) raised $100 million in an IPO on Thursday, June 20th 2019. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, BofA Merrill Lynch and Cowen and Company served as the underwriters for the IPO and Oppenheimer was co-manager. What is Personalis' stock symbol? Personalis trades on the NASDAQ under the ticker symbol "PSNL." How do I buy shares of Personalis? Shares of PSNL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Personalis' stock price today? One share of PSNL stock can currently be purchased for approximately $7.92. How big of a company is Personalis? Personalis has a market capitalization of $249.24 million and generates $65.21 million in revenue each year. The company earns $-25,080,000.00 in net income (profit) each year or ($1.39) on an earnings per share basis. Personalis employs 147 workers across the globe. View additional information about Personalis. What is Personalis' official website? The official website for Personalis is http://www.personalis.com/. How can I contact Personalis? Personalis' mailing address is 1330 O`BRIEN DRIVE, MENLO PARK CA, 94025. The company can be reached via phone at 650-752-1300 or via email at [email protected] This page was last updated on 4/7/2020 by MarketBeat.com StaffFeatured Article: Circuit Breakers
